SEAMARK : phase II study of first-line encorafenib and cetuximab plus pembrolizumab for MSI-H/dMMR BRAFV600E-mutant mCRC
Elez, Elena (Universitat Autònoma de Barcelona. Departament de Medicina)
Kopetz, Scott (University of Texas MD Anderson Cancer Center)
Tabernero, Josep (Universitat de Vic - Universitat Central de Catalunya)
Bekaii-Saab, Tanios (Mayo Clinic)
Taieb, Julien (Université de Paris)
Yoshino, Takayuki (National Cancer Center Hospital East)
Manji, Gulam (Columbia University Irving Medical Center & NewYork-Presbyterian Hospital)
Fernandez, Kathrine (Pfizer Global Product Development-Oncology)
Abbattista, Antonello (Pfizer Global Product Development-Oncology)
Zhang, Xiaosong (Pfizer, New York, NY, USA)
Morris, Van K (University of Texas MD Anderson Cancer Center)

Fecha:	2024
Resumen:	Patients with both BRAF V600E mutations and microsatellite instability-high (MSI-H)/mismatch repair-deficient (dMMR) metastatic colorectal cancer (mCRC) have poor prognosis. Currently, there are no specifically targeted first-line treatment options indicated for patients with mCRC whose tumors harbor both molecular aberrations. Pembrolizumab is a checkpoint inhibitor approved for the treatment of MSI-H/dMMR mCRC, and the BRAF inhibitor encorafenib, in combination with cetuximab, is approved for previously treated BRAF V600E-mutant mCRC. Combination of pembrolizumab with encorafenib and cetuximab may synergistically enhance antitumor activity in patients with BRAF V600E-mutant, MSI-H/dMMR mCRC. SEAMARK is a randomized phase II study comparing the efficacy of the combination of pembrolizumab with encorafenib and cetuximab versus pembrolizumab alone in patients with previously untreated BRAF V600E-mutant, MSI-H/dMMR mCRC.
Derechos:	Aquest document està subjecte a una llicència d'ús Creative Commons. Es permet la reproducció total o parcial, la distribució, i la comunicació pública de l'obra, sempre que no sigui amb finalitats comercials, i sempre que es reconegui l'autoria de l'obra original. No es permet la creació d'obres derivades.
Lengua:	Anglès
Documento:	Article ; recerca ; Versió publicada
Materia:	BRAF V600 ; Cetuximab ; dMMR ; Encorafenib ; Immunotherapy ; Metastatic colorectal cancer ; MSI-H ; Pembrolizumab ; Targeted therapy ; Triplet combination therapy
Publicado en:	Future oncology (London, England), Vol. 20, Num. 11 (April 2024) , p. 653-663, ISSN 1744-8301

DOI: 10.2217/fon-2022-1249
PMID: 37815847

11 p, 3.7 MB

El registro aparece en las colecciones:
Artículos > Artículos de investigación
Artículos > Artículos publicados